Genetic Testing Industry

The global genetic testing market size was estimated at USD 11.71 billion in 2024 and is anticipated to expand at a compound annual growth rate (CAGR) of 22.5% from 2025 to 2030. One of the primary factors expected to drive this growth is the increasing demand for newborn screening programs. These programs are becoming more widespread and critical in identifying potential genetic disorders at an early stage. For instance, in the United States, newborn screening programs currently assess infants for over 60 different medical conditions, as noted by the American Association for Clinical Chemistry. To ensure consistency and effectiveness, the U.S. Department of Health and Human Services oversees a Recommended Uniform Screening Panel (RUSP), which contains a curated list of genetic disorders that are recommended for mandatory screening across the country. These recommendations are founded on historical data regarding disease frequency and severity, which reinforces the need for early diagnosis and timely medical intervention in infants.

Pharmacogenomics testing is playing an increasingly essential role in the field of personalized medicine, as it aids healthcare professionals in selecting the most suitable drugs and determining the correct dosages for individual patients. This is particularly important for minimizing adverse drug reactions and optimizing therapeutic outcomes. The Association for Molecular Pathology (AMP) has taken notable steps toward the standardization of pharmacogenomics testing across clinical laboratories. For example, in August 2022, the AMP issued a set of detailed recommendations to guide the design and validation of clinical genotyping assays targeting genes such as NUDT15 and TPMT. These guidelines identify a minimum set of genetic variants, or alleles, that laboratories should screen for in order to detect patients who may be at increased risk for thiopurine toxicity. By enabling more accurate identification of at-risk individuals, these efforts contribute to improved safety and effectiveness in drug therapy.

Although the COVID-19 pandemic posed significant challenges to public health systems and global economies, it also had a moderately beneficial impact on the genetic testing sector. This is because the pandemic underscored the importance of genetic testing technologies in the research and development of medical treatments. For instance, during the pandemic, researchers employed genotoxic testing methods to assess the effectiveness of specific drugs in combating COVID-19. In September 2020, one such research team conducted a study to evaluate the potential of Chloroquine (CQ) and Hydroxychloroquine (HCQ) as preventive treatments against the virus. This study demonstrated the relevance of genetic toxicology tests in assessing drug safety and efficacy, further emphasizing the role of genetic testing in advancing medical science. As a result, such research applications are expected to support the continued and stable growth of the genetic testing market in the post-pandemic era.

Curious about the Genetic Testing Market, Download your FREE sample copy now and get a sneak peek into the latest insights and trends.

Frequently Asked Questions About This Report

1. What is the current size of the genetic testing market and its future outlook?

The global genetic testing market is currently valued at over USD 11 billion and is expected to grow rapidly at a compound annual growth rate (CAGR) of around 22%, reaching approximately USD 39 billion by 2030. This growth is driven by increasing demand for personalized medicine, early disease detection, and consumer interest in ancestry and health traits.

2. What factors are driving the growth of the genetic testing market?

Several key factors are fueling market growth:

• Rising demand for early disease diagnosis and risk assessment, particularly for cancers and rare genetic disorders.
• Increased use of genetic testing in preventive healthcare and wellness monitoring.
• Advancements in technologies such as next-generation sequencing (NGS), making testing faster and more affordable.
• Growing popularity of direct-to-consumer (DTC) tests for ancestry, diet, fitness, and health-related traits.
• Government support for newborn screening programs and rare disease initiatives.

3. How is the genetic testing market segmented?

The market is segmented in several ways:

• By Technology: Includes next-generation sequencing (NGS), polymerase chain reaction (PCR), microarrays, and fluorescence in situ hybridization (FISH).
• By Application: Covers ancestry & ethnicity, disease carrier screening, health & wellness risk, newborn screening, and pharmacogenetics.
• By Product: Divided into consumables (e.g., kits and reagents), equipment, and software & services.
• By Distribution Channel: Online platforms and offline facilities (like clinics and pharmacies).
• By End-Use: Hospitals & clinics, diagnostic labs, and home users.

4. Which segment holds the largest share of the market?

• Technology: Next-generation sequencing (NGS) holds the largest market share due to its speed, accuracy, and scalability.
• Application: Health & wellness risk analysis leads, driven by consumer curiosity about genetic predispositions.
• Product: Consumables dominate the market, as they are used repeatedly across testing procedures.
• End-Use: Hospitals and clinics account for the largest revenue share because of their widespread use in diagnostics.

5. What are the fastest-growing areas within the market?

• Online distribution channels are expanding rapidly due to the popularity of at-home testing kits.
• Asia Pacific is the fastest-growing regional market, thanks to improving healthcare infrastructure and rising awareness of genetic conditions.
• Direct-to-consumer (DTC) testing services are gaining momentum, especially for non-clinical purposes like ancestry and lifestyle optimization.

6. What are the challenges facing the genetic testing industry?

• Privacy and data security concerns related to storing and handling genetic information.
• Regulatory uncertainty, especially around DTC tests and data ownership.
• Limited reimbursement for genetic tests in some countries.
• Lack of awareness or misinterpretation of test results among the general public.

Order a free sample PDF of the Genetic Testing Market Intelligence Study, published by Grand View Research.